UNITED CANNABIS CORP
CNAB evidence brief
What we can confirm
- BioSniper Score:
- 2.7 / 10
- Lead Asset:
- prana bio nutrient medicinals (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CNAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
prana bio nutrient medicinals (Preclinical)
Next Catalyst
—
Tracking 1 pipeline candidate for UNITED CANNABIS CORP.
Run UNITED CANNABIS CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available UNITED CANNABIS CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is UNITED CANNABIS CORP's lead drug candidate?
UNITED CANNABIS CORP's most advanced tracked candidate is prana bio nutrient medicinals (Preclinical) for pain, neuropathy, arthritis, MS, IBS, autism, seizures, eczema, sleep, anxiety, head trauma, opioid dependency and clinical endocannabinoid deficiencies.
Who is the CEO of UNITED CANNABIS CORP?
Earnest Blackmon is the chief executive officer of UNITED CANNABIS CORP (CNAB).
What therapeutic areas does UNITED CANNABIS CORP focus on?
UNITED CANNABIS CORP develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.